
## Richard J Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12008062/publications.pdf Version: 2024-02-01



RICHARD I LEE

#	Article	IF	CITATIONS
1	Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proceedings of the United States of America, 2010, 107, 18392-18397.	7.1	1,454
2	Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells. Science Translational Medicine, 2013, 5, 179ra47.	12.4	910
3	RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science, 2015, 349, 1351-1356.	12.6	614
4	Isolation and Characterization of Circulating Tumor Cells from Patients with Localized and Metastatic Prostate Cancer. Science Translational Medicine, 2010, 2, 25ra23.	12.4	474
5	Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway. Molecular and Cellular Biology, 2000, 20, 672-683.	2.3	342
6	The Cyclins and Cyclin-Dependent Kinase Inhibitors in Hormonal Regulation of Proliferation and Differentiation*. Endocrine Reviews, 1999, 20, 501-534.	20.1	299
7	Integration of Rac-dependent Regulation of Cyclin D1 Transcription through a Nuclear Factor-κB-dependent Pathway. Journal of Biological Chemistry, 1999, 274, 25245-25249.	3.4	260
8	Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer. Cancer Discovery, 2012, 2, 995-1003.	9.4	257
9	Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. European Urology, 2017, 71, 952-960.	1.9	253
10	Fos Family Members Induce Cell Cycle Entry by Activating Cyclin D1. Molecular and Cellular Biology, 1998, 18, 5609-5619.	2.3	221
11	pp60v- Induction of Cyclin D1 Requires Collaborative Interactions between the Extracellular Signal-regulated Kinase, p38, and Jun Kinase Pathways. Journal of Biological Chemistry, 1999, 274, 7341-7350.	3.4	214
12	Activation of the cyclin D1 Gene by the E1A-associated Protein p300 through AP-1 Inhibits Cellular Apoptosis. Journal of Biological Chemistry, 1999, 274, 34186-34195.	3.4	166
13	Inhibition of Cyclin D1 Kinase Activity Is Associated with E2F-Mediated Inhibition of Cyclin D1 Promoter Activity through E2F and Sp1. Molecular and Cellular Biology, 1998, 18, 3212-3222.	2.3	152
14	Angiotensin II Activation of Cyclin D1-dependent Kinase Activity. Journal of Biological Chemistry, 1996, 271, 22570-22577.	3.4	130
15	Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1028-1036.	0.8	122
16	Circulating tumour cells—monitoring treatment response in prostate cancer. Nature Reviews Clinical Oncology, 2014, 11, 401-412.	27.6	110
17	An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. Cancer Discovery, 2018, 8, 288-303.	9.4	107
18	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology, 2018, 73, 715-723.	1.9	105

**RICHARD J LEE** 

#	Article	IF	CITATIONS
19	Expression of β-globin by cancer cells promotes cell survival during blood-borne dissemination. Nature Communications, 2017, 8, 14344.	12.8	96
20	Transforming Potential of Dbl Family Proteins Correlates with Transcription from the Cyclin D1 Promoter but Not with Activation of Jun NH2-terminal Kinase, p38/Mpk2, Serum Response Factor, or c-Jun. Journal of Biological Chemistry, 1998, 273, 16739-16747.	3.4	84
21	Emerging Therapies to Prevent Skeletal Morbidity in Men With Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 3705-3714.	1.6	70
22	A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases. Clinical Cancer Research, 2013, 19, 3088-3094.	7.0	69
23	Disparities in Cancer Care and the Asian American Population. Oncologist, 2021, 26, 453-460.	3.7	59
24	Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogrammed primary prostate cancer cells Oncotarget, 2014, 5, 1683-1698.	1.8	59
25	Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate Cancer. Journal of Urology, 2010, 183, 2200-2205.	0.4	51
26	Nerve Growth Factor Regulation of Cyclin D1 in PC12 Cells through a p21 <sup>RAS</sup> Extracellular Signal-regulated Kinase Pathway Requires Cooperative Interactions between Sp1 and Nuclear Factor-κB. Molecular Biology of the Cell, 2008, 19, 2566-2578.	2.1	44
27	Cell cycle genes in chondrocyte proliferation and differentiation. Matrix Biology, 1999, 18, 109-120.	3.6	43
28	p27Kip1 Repression of ErbB2-Induced Mammary Tumor Growth in Transgenic Mice Involves Skp2 and Wnt/β-Catenin Signaling. Cancer Research, 2006, 66, 8529-8541.	0.9	39
29	The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells. Oncotarget, 2014, 5, 10678-10691.	1.8	36
30	ErbB-2-induced mammary tumor growth: the role of cyclin D1 and p27Kip1. Biochemical Pharmacology, 2002, 64, 827-836.	4.4	33
31	Targeting MET and Vascular Endothelial Growth Factor Receptor Signaling in Castration-Resistant Prostate Cancer. Cancer Journal (Sudbury, Mass ), 2013, 19, 90-98.	2.0	32
32	Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 501-508.	1.6	31
33	The effect of tumor necrosis factor-α and cAMP on induction of AP-1 activity in MA-10 tumor leydig cells. Endocrine, 1997, 6, 317-324.	2.3	30
34	Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 440-446.	1.9	29
35	Branched Chain RNA <i>In Situ</i> Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer. Clinical Cancer Research, 2017, 23, 363-369.	7.0	23
36	Reduced Cyclin D1 Expression in the Cerebella of Nutritionally Deprived Rats Correlates with Developmental Delay and Decreased Cellular DNA Synthesis. Journal of Neuropathology and Experimental Neurology, 1996, 55, 1009-1020.	1.7	22

**RICHARD J LEE** 

#	Article	IF	CITATIONS
37	Contemporary Therapeutic Approaches Targeting Bone Complications in Prostate Cancer. Clinical Genitourinary Cancer, 2010, 8, 29-36.	1.9	18
38	Viral integration in BK polyomavirus-associated urothelial carcinoma in renal transplant recipients: multistage carcinogenesis revealed by next-generation virome capture sequencing. Oncogene, 2020, 39, 5734-5742.	5.9	17
39	Characterization of the effects of defined, multidimensional culture conditions on conditionally reprogrammed primary human prostate cells. Oncotarget, 2018, 9, 2193-2207.	1.8	16
40	Cell-free and circulating tumor cell–based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine?. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 490-501.	1.6	11
41	Cabozantinib and Prostate Cancer: Inhibiting Seed and Disrupting Soil?. Clinical Cancer Research, 2014, 20, 525-527.	7.0	10
42	Predicting new drug indications for prostate cancer: The integration of an in silico proteochemometric network pharmacology platform with patientâ€derived primary prostate cells. Prostate, 2020, 80, 1233-1243.	2.3	9
43	Charting a Path Towards Asian American Cancer Health Equity: A Way Forward. Journal of the National Cancer Institute, 2022, 114, 792-799.	6.3	9
44	Genome-wide profiling of BK polyomavirus integration in bladder cancer of kidney transplant recipients reveals mechanisms of the integration at the nucleotide level. Oncogene, 2021, 40, 46-54.	5.9	8